Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...5152535455565758596061...123124»
  • ||||||||||  Sutent (sunitinib) / Pfizer
    Clinical, P1 data, Journal:  Investigational drugs for the treatment of thymic cancer: a focus on phase 1 and 2 clinical trials. (Pubmed Central) -  Aug 14, 2022   
    Sunitinib and Lenvatinib showed response rates of 26% and 38%, respectively, and ICIs showed durable responses in 20-25% in thymic carcinoma patients (TCs). Both approaches are mainly active in TCs, therefore new treatment options for thymomas is an unmet medical need.Two major new therapeutic strategies are ICIs combinations with other drugs and drugs that target pathways that are dysregulated in TETs.Future challenges include the development of preclinical models to help identify novel targets and test new treatment strategies, and randomized clinical trials to provide reliable evidence based on survival endpoints.
  • ||||||||||  lenvatinib / Generic mfg.
    Preclinical, Journal:  Preclinical Therapeutic Evaluation of Lenvatinib-Eluting Microspheres for Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma. (Pubmed Central) -  Aug 14, 2022   
    Both approaches are mainly active in TCs, therefore new treatment options for thymomas is an unmet medical need.Two major new therapeutic strategies are ICIs combinations with other drugs and drugs that target pathways that are dysregulated in TETs.Future challenges include the development of preclinical models to help identify novel targets and test new treatment strategies, and randomized clinical trials to provide reliable evidence based on survival endpoints. LEN-TACE using IA delivery of LEN-EM demonstrated an effective therapeutic efficacy in an HCC rat animal model.
  • ||||||||||  lenvatinib / Generic mfg.
    Clinical, Retrospective data, Journal, Real-world evidence:  Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter Study. (Pubmed Central) -  Aug 13, 2022   
    Additionally, macrovascular invasion (HR 1.55, 95% CI 1.02-2.37, p=0.041) and an AFP ≥200 ng/mL (HR 1.56, 95% CI 1.03-2.34, p=0.034) were confirmed as independent negative prognostic factors in our cohort of patients with advanced HCC. Overall, our data confirm the efficacy of lenvatinib as first-line treatment and did not reveal new or unexpected side effects in a large retrospective Caucasian real-world cohort, supporting the use of lenvatinib as meaningful alternative for patients that cannot be treated with IO-based combinations in first-line HCC.
  • ||||||||||  Journal, IO biomarker:  Emerging drugs for the treatment of hepatocellular carcinoma. (Pubmed Central) -  Aug 11, 2022   
    The inclusion of immunotherapy to systemic therapy has revolutionalized the field of HCC treatment. Identificantion of the appropriate combination and sequence of systemic therapy coupled with discovery of reliable HCC biomarkers will lead to improved survival and inidividulized HCC therapy.
  • ||||||||||  lenvatinib / Generic mfg.
    Journal:  CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells. (Pubmed Central) -  Aug 10, 2022   
    After drug withdrawal, the capacity of forming colonies was significantly impaired, suggesting that the anti-tumor efficacy of abemaciclib and lenvatinib combination was persistent. Our pre-clinical results demonstrate the effectiveness of the simultaneous combination of CDK4/6 inhibitors with lenvatinib in HCC cell models, suggesting that this combination may be worthy of further investigation as a therapeutic approach for the treatment of advanced HCC.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date:  PLANE-PC: Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer (clinicaltrials.gov) -  Aug 8, 2022   
    P2,  N=50, Recruiting, 
    No abstract available Trial completion date: Jul 2023 --> Oct 2023 | Trial primary completion date: Oct 2022 --> Oct 2023
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    ROR1-CAR T-cells as novel treatment strategy for anaplastic thyroid carcinoma () -  Aug 6, 2022 - Abstract #ITOC2022ITOC_101;    
    Animal models are ongoing and will be finalized at presentation. Conclusions In summary our data proof ROR1 as a viable and specific target for several types of thyroid carcinoma which is the basis for the design of a clinical phase I trial using ROR1-CAR T-cells in metastasized ATC and PDTC patients.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Herceptin (trastuzumab) / Roche, Jemperli (dostarlimab) / GSK
    Review, Journal, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker:  Incorporating Molecular Diagnostics into Treatment Paradigms for Endometrial Cancer. (Pubmed Central) -  Aug 6, 2022   
    For p53 abnormal tumors, which have the worst prognosis, there are several new treatment approaches including lenvatinib and pembrolizumab, trastuzumab, and possibly a future role for PARP inhibitors in the homologous recombination deficiency (HRD) p53 abnormal population...Further research is needed to better characterize biomarkers for prognosis and identify targeted treatments within the p53 wild-type (p53 WT)/no specific molecular profile (NSMP) cohort. Upcoming studies are evaluating adjuvant treatment by molecular subtype and will determine the next steps for precision medicine in endometrial cancer.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open, Checkpoint inhibition, Metastases:  Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Na (clinicaltrials.gov) -  Aug 5, 2022   
    P2,  N=30, Recruiting, 
    Upcoming studies are evaluating adjuvant treatment by molecular subtype and will determine the next steps for precision medicine in endometrial cancer. Not yet recruiting --> Recruiting
  • ||||||||||  GNOS-PV02 / Geneos Therap, Keytruda (pembrolizumab) / Merck (MSD)
    Personalized DNA neoantigen vaccine (GNOS-PV02) in combination with plasmid IL-12 and pembrolizumab as second-line (2L) treatment for advanced hepatocellular carcinoma (HCC) (205ABC) -  Aug 4, 2022 - Abstract #SITC2022SITC_193;    
    P1/2
    Methods Patients with unresectable or metastatic HCC and progression or intolerance on first-line therapy with tyrosine kinase inhibitors (sorafenib or lenvatinib) are enrolled...Conclusions GNOS-PV02 + INO-9012 combined with pembrolizumab in the 2L setting was well tolerated and induced tumor-neoantigen-directed CD8+ T cells and TILs...Trial Registration NCT04251117 Ethics Approval For GT-30 trial, the protocols were approved by Johns Hopkins Medicine Review Boards (CR00039002/IRB00227771), Icahn School of Medicine-Program for the Protection of Human Subjects (20-00076 GCO#1), and Northern A Health and Disability Ethics committee (Ethics ref: 20/NTA), respectively. Written informed consent was obtained from each patient prior to the patient participating in the trial.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    KEYNOTE-495/KeyImPaCT: updated analysis of a biomarker-directed, randomized, phase 2 trial of pembrolizumab-based combination therapy for non-small cell lung cancer (Hall B2) -  Aug 4, 2022 - Abstract #SITC2022SITC_109;    
    P2
    Although response in the pembrolizumab+favezelimab arm did not reach the efficacy bar, there was a trend toward improved ORR in the Tcell inf GEP non-low TMB high subgroup versus the other 3 biomarker-defined subgroups; median PFS and OS were also numerically longer in the Tcell inf GEP non-low TMB high subgroup compared with the other 3 biomarker-defined subgroups. Prospective assessment of dual biomarkers, as performed in this study, may help identify patients with NSCLC most likely to respond to pembrolizumab-based combination therapies.
  • ||||||||||  lenvatinib / Generic mfg.
    Journal:  miR-3154 promotes hepatocellular carcinoma progression via suppressing HNF4α. (Pubmed Central) -  Aug 3, 2022   
    Analysis of patient cohort and patient-derived xenografts (PDXs) further suggest that miR-3154 might predict lenvatinib clinical benefit in HCC patients. In conclusion, we reveal the crucial role of miR-3514 in HCC progression and lenvatinib response, suggesting potential therapeutic targets for HCC.